No profile data available.
Enliven Therapeutics, Inc. (ELVN) is a healthcare company in the additional cancer treatment drugs industry, based in Boulder, United States, with about 67 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$103.69 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $3.00 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Enliven Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$3.00 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Relay Therapeutics, Inc. (RLAY), Ideaya Biosciences, Inc. (IDYA), Arcus Biosciences, Inc. (RCUS), Zai Lab Limited (ZLAB).